Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency
use as therapeutics. Here, we identify 377 human monoclonal antibodies (mAbs) …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

Most antibodies isolated from individuals with coronavirus disease 2019 (COVID-19) are
specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However …

Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …

Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …

The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly
develop therapeutics and prophylactics against SARS-CoV-2. The SARS-CoV-2 spike …

As the coronavirus disease 2019 (COVID-19) pandemic continues, there is a strong need for
highly potent monoclonal antibodies (mAbs) that are resistant against severe acute …

Antibody-mediated immunity plays a crucial role in protection against SARS-CoV-2 infection.
We isolated a panel of neutralizing anti-receptor-binding domain (RBD) antibodies elicited …

SARS-CoV-2, the novel coronavirus responsible for the ongoing COVID-19 pandemic, has
been spreading rampantly. The global scientific community has responded rapidly to …